Kosan Biosciences' Series C Round

Kosan Biosciences raised a round of funding on March 17, 2000.

is developing two new classes of anticancer agents: heat shock protein 90 (Hsp90) inhibitors and epothilones. Hsp90 inhibitors target multiple pathways involved in cancer cell growth and survival and …

Articles about Kosan Biosciences' Series C Round: